Wren Therapeutics, founded in 2016, is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden). The company is based at the University of Cambridge, in the recently opened Chemistry of Health Centre, and is focused on drug discovery and development for protein misfolding diseases.
The scientific founders include:
About Protein Misfolding Diseases
Wren is focused on drug discovery and development for protein misfolding diseases. Alzheimer's and Parkinson's diseases are widely known examples of this group of medical disorders, but others include type-2 diabetes and many rare diseases amongst the more than 50 in total.
Protein misfolding diseases are one of the most critical global healthcare challenges of the 21st century. However, current strategies - in particular those driven by traditional drug discovery and biological approaches - have proven, at least to date, to be ineffective.
Wren's Proprietary Approach
Wren’s approach is built on concepts from the physical sciences and is based on more than a decade of research focused on the chemical kinetics of the protein misfolding process.
These advances make it possible to map, and selectively modulate, the complex and non-linear chemical kinetic networks associated with misfolding proteins and disease, creating a predictive and quantitatively driven platform that has the potential to radically advance drug discovery for this class of diseases.
Wren is using its unique approach to develop a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases.